GlassScriptPhysician profile
Brenna Gillis
NPI 1639548241
$2,804.09
in general payments reported to CMS, 2019-2025
23 companies · $949 in 2025
The $949 reported for 2025 was more than what 79% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $245 · 2022: $167 · 2023: $646 · 2024: $797 · 2025: $949.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,392.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,392.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $342.50 | 2023-2025 | Azstarys |
| Otsuka America Pharmaceutical, INC. | $304.94 | 2021-2025 | Rexulti, Abilify Maintena |
| Takeda Pharmaceuticals U.S.A., INC. | $253.68 | 2021-2025 | Trintellix |
| Vanda Pharmaceuticals INC. | $228.58 | 2024-2025 | Fanapt, Hetlioz |
| Abbvie INC. | $202.65 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $201.36 | 2023-2025 | Spravato |
| Alkermes, INC. | $192.68 | 2022-2025 | Aristada, Lybalvi |
| Axsome Therapeutics, INC. | $189.53 | 2023-2025 | Auvelity, Sunosi |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $178.11 | 2021-2025 | Caplyta |
| Neurocrine Biosciences, INC. | $170.80 | 2023-2025 | Ingrezza |
| Lundbeck LLC | $109.61 | 2021-2025 | Rexulti, Brintellix |
| Ironshore Pharmaceuticals INC. | $73.65 | 2021-2023 | Jornay Pm |
| Supernus Pharmaceuticals, INC. | $65.94 | 2021-2023 | Qelbree |
| Tris Pharma INC | $51.51 | 2023-2025 | Dyanavel Xr |
| Teva Pharmaceuticals USA, INC. | $50.88 | 2024 | Austedo Xr |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $45.52 | 2021-2022 | |
| Tempus Ai, INC | $29.32 | 2024 | |
| Harmony Biosciences LLC | $25.05 | 2025 | |
| Jazz Pharmaceuticals INC. | $22.18 | 2022 | |
| Noven Therapeutics, LLC | $19.49 | 2024 | Secuado, Xelstrym |
| Bausch Health US, LLC | $17.84 | 2024 | Aplenzin |
| Neos Therapeutics, LP | $15.69 | 2022 | |
| Eisai INC. | $12.58 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brenna Gillis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.